Catalent Dirección

Dirección controles de criterios 2/4

El CEO de Catalent's es Alessandro Maselli , nombrado en Jul 2022, tiene una permanencia de 1.75 años. compensación anual total es $6.58M, compuesta por 14% salario y 86% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.019% de las acciones de la empresa, por valor de $1.89M. La antigüedad media del equipo directivo y de la junta directiva es de 1.5 años y 8.7 años, respectivamente.

Información clave

Alessandro Maselli

Chief Executive Officer (CEO)

US$6.6m

Compensación total

Porcentaje del salario del CEO	14.0%
Permanencia del CEO	1.8yrs
Participación del CEO	0.02%
Permanencia media de la dirección	1.5yrs
Promedio de permanencia en la Junta Directiva	8.8yrs

Actualizaciones recientes de la dirección

Recent updates

Catalent to make Sarepta Therapeutics' muscle wasting gene therapy under supply deal

Jan 05

An Intrinsic Calculation For Catalent, Inc. (NYSE:CTLT) Suggests It's 27% Undervalued

Dec 27

Humanigen to pay Catalent Pharma $12M to settle supply agreement dispute

Dec 22

Catalent falls after new short call from Glasshouse Research

Dec 08

Catalent Q1 2023 Earnings Preview

Oct 31

These 4 Measures Indicate That Catalent (NYSE:CTLT) Is Using Debt Extensively

Oct 26

Catalent: Charting A Post-Covid Future

Oct 19

Calculating The Fair Value Of Catalent, Inc. (NYSE:CTLT)

Sep 16

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Alessandro Maselli en comparación con los beneficios de Catalent?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$1b
Dec 31 2023	n/a	n/a	-US$1b
Sep 30 2023	n/a	n/a	-US$1b
Jun 30 2023	US$7m	US$925k	-US$256m
Mar 31 2023	n/a	n/a	US$21m
Dec 31 2022	n/a	n/a	US$389m
Sep 30 2022	n/a	n/a	US$399m
Jun 30 2022	US$3m	US$654k	US$483m
Mar 31 2022	n/a	n/a	US$485m
Dec 31 2021	n/a	n/a	US$561m
Sep 30 2021	n/a	n/a	US$544m
Jun 30 2021	US$5m	US$640k	US$529m
Mar 31 2021	n/a	n/a	US$494m
Dec 31 2020	n/a	n/a	US$289m
Sep 30 2020	n/a	n/a	US$250m
Jun 30 2020	US$3m	US$483k	US$173m
Mar 31 2020	n/a	n/a	US$104m
Dec 31 2019	n/a	n/a	US$124m
Sep 30 2019	n/a	n/a	US$138m
Jun 30 2019	US$2m	US$450k	US$132m

Compensación vs. Mercado: La compensación total de Alessandro($USD6.58M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD13.51M).

Compensación vs. Ingresos: La compensación de Alessandro ha aumentado mientras la empresa no es rentable.

CEO

Alessandro Maselli (51 yo)

1.8yrs

Permanencia

US$6,583,672

Compensación

Mr. Alessandro Maselli has been President of Catalent Pharma Solutions, Inc. from February 2019 and serves as its Director since July 01, 2022 and is its Chief Executive Officer and was its Chief Operation...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
John Greisch	Executive Chairman of the Board	6.3yrs	US$400.86k	0.024% $ 2.4m
Alessandro Maselli	President	1.8yrs	US$6.58m	0.019% $ 1.9m
Aristippos Gennadios	Group President of Pharma & Consumer Health Segment	5.3yrs	US$3.80m	0.030% $ 3.1m
Ricky Hopson	President	less than a year	US$972.31k	0.0045% $ 454.9k
Matti Masanovich	Senior VP & CFO	less than a year	sin datos	sin datos
Michael Hatzfeld	VP & Chief Accounting Officer	less than a year	sin datos	sin datos
Charles Lickfold	Senior VP & Chief Information Officer	4yrs	sin datos	0.0060% $ 605.9k
Paul Surdez	Vice President of Investor Relations	4.3yrs	sin datos	sin datos
Joseph Ferraro	Senior VP	1.3yrs	sin datos	sin datos
Michael Grippo	Senior Vice President of Strategy & Corporate Development	4.6yrs	sin datos	0.013% $ 1.3m
Lisa Evoli	Senior VP & Chief Human Resources Officer	less than a year	sin datos	sin datos
Scott Gunther	Senior Vice President of Quality & Regulatory Affairs	7yrs	sin datos	0.016% $ 1.6m

1.5yrs

Permanencia media

51yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de CTLT no se considera experimentado ( 1.5 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
John Greisch	Executive Chairman of the Board	6.3yrs	US$400.86k	0.024% $ 2.4m
Alessandro Maselli	President	1.8yrs	US$6.58m	0.019% $ 1.9m
Donald Morel	Independent Director	8.5yrs	US$384.95k	0.026% $ 2.6m
Rolf Classon	Independent Director	9.8yrs	US$384.95k	0.0061% $ 615.9k
Daniel R. Marshak	Member of Advisory Board	8.8yrs	sin datos	sin datos
Jack Stahl	Independent Lead Director	9.8yrs	US$395.11k	0.015% $ 1.6m
Gregory Lucier	Independent Director	9.1yrs	US$387.61k	0.00077% $ 77.5k
J. Carroll	Independent Director	8.8yrs	US$426.36k	0.018% $ 1.8m
Edward Robinson	Member of Advisory Board	9.1yrs	sin datos	sin datos
Michael Buckley	Member of Advisory Board	8.8yrs	sin datos	sin datos
Carolyn Bertozzi	Member of Scientfic & Advisory Board	8.8yrs	sin datos	sin datos
Barry Buckland	Member of Advisory Board	8.8yrs	sin datos	sin datos

8.8yrs

Permanencia media

66yo

Promedio de edad

Junta con experiencia: La junta directiva de CTLT se considera experimentada (8.7 años de antigüedad promedio).

Catalent Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Insufficient new directors

Insufficient new directors

Catalent, Inc. Announces Executive Changes

Catalent, Inc., Annual General Meeting, Jan 25, 2024

Catalent, Inc. Appoints David McErlane as Group President of Catalent’s Biologics segment, Effective September 25, 2023

Catalent, Inc. Appoints Steven Barg as A Member of the Board of Directors

Recent updates

Price target increased by 15% to US$63.50

Insufficient new directors

Catalent, Inc. announced delayed 10-Q filing

Insufficient new directors

Catalent - Novo Holdings Merger: Attractive Spread

Novo Holdings A/S entered into an agreement to acquire Catalent, Inc. (NYSE:CTLT) from Elliott Investment Management L.P. and other for $11.7 million.

Novo Holdings A/S entered into an agreement to acquire Catalent, Inc. (NYSE:CTLT) from Elliott Investment Management L.P. and other for $11.7 million.

Catalent, Inc. to Report Q2, 2024 Results on Feb 09, 2024

Catalent, Inc. Announces Executive Changes

Catalent, Inc., Annual General Meeting, Jan 25, 2024

Catalent: Debt Remains An Overhang

Catalent, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024

Catalent, Inc. announced delayed 10-Q filing

Catalent, Inc. to Report Q1, 2024 Results on Nov 15, 2023

Catalent Remains Overvalued

Catalent, Inc. Appoints David McErlane as Group President of Catalent’s Biologics segment, Effective September 25, 2023

Catalent Receives NYSE Notice Regarding Late Form 10-K Filing

Catalent, Inc. Appoints Steven Barg as A Member of the Board of Directors

Catalent, Inc. announced delayed annual 10-K filing

Full year 2023 earnings: EPS misses analyst expectations

Catalent, Inc. Announces Board Changes

Catalent, Inc. to Report Q4, 2023 Results on Aug 29, 2023

Calculating The Intrinsic Value Of Catalent, Inc. (NYSE:CTLT)

Insufficient new directors

Catalent, Inc. Announces Executive Changes

Catalent: Myriad Issues To Fix

Catalent, Inc.(NYSE:CTLT) dropped from Russell 1000 Growth Index

Catalent, Inc. Appoints Matti Masanovich as Senior Vice President, Effective July 5, 2023

Catalent Regains Compliance with NYSE Continued Listing Standards

Catalent, Inc. Reports Impairment Results for the Quarter Ended March 31, 2023

New minor risk - Earnings quality

Catalent, Inc. Updates Revenue Guidance for the Full Year of 2023

Catalent, Inc. announced delayed 10-Q filing

Price target decreased by 7.6% to US$63.17

Catalent, Inc. Reduces Revenue Guidance for the Fiscal Year 2023

Now 30% undervalued after recent price drop

Catalent (NYSE:CTLT) Has A Somewhat Strained Balance Sheet

Insider recently sold US$72k worth of stock

Investor sentiment improves as stock rises 15%

Now 22% undervalued after recent price drop

Consensus EPS estimates fall by 10%

Investor sentiment deteriorates as stock falls 29%

A Look At The Intrinsic Value Of Catalent, Inc. (NYSE:CTLT)

Catalent Appoints Joseph A. Ferraro as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary

Price target increased by 11% to US$82.36

Catalent, Inc. Reiterates Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Danaher Reportedly Expresses Takeover Interest in Catalent

Investor sentiment improves as stock rises 27%

Why did Catalent stock soar today? Potential takeover by Danaher

We Think Catalent (NYSE:CTLT) Is Taking Some Risk With Its Debt

Catalent, Inc. to Report Q2, 2023 Results on Feb 07, 2023

Catalent, Inc. Announces the Appointment of Ricardo Zayas as Senior Vice President, Operations, Biologics North America

Catalent to make Sarepta Therapeutics' muscle wasting gene therapy under supply deal

An Intrinsic Calculation For Catalent, Inc. (NYSE:CTLT) Suggests It's 27% Undervalued

Humanigen to pay Catalent Pharma $12M to settle supply agreement dispute

Catalent, Inc. Announces Director Changes

Catalent falls after new short call from Glasshouse Research

Now 23% undervalued after recent price drop

Investor sentiment improved over the past week

Price target decreased to US$76.00

Investor sentiment deteriorated over the past week

Insider recently sold US$161k worth of stock

Price target decreased to US$91.50

Catalent, Inc. Revises Revenue Guidance for the Full Year 2023

Catalent Q1 2023 Earnings Preview

These 4 Measures Indicate That Catalent (NYSE:CTLT) Is Using Debt Extensively

Catalent: Charting A Post-Covid Future

Catalent, Inc. to Report Q1, 2023 Results on Nov 01, 2022